Key Points:
CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab … Read more
by Nichole Tucker
The DUO-O press release went out on 4/5/2023. It suggests that adding immunotherapy to PARP inhibitor maintenance therapy for newly diagnosed ovarian cancer patients that have finished first-line platinum treatment may be beneficial. We are eagerly awaiting … Read more
by Devin McLaughlin
Neoadjuvant therapy with olaparib showed feasibility for women with germline-mutant ovarian cancer, according to results of the NOW trial presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Researchers observed favorable surgical outcomes — even … Read more
by Jason Harris
Botensilimab (AGEN1181) in combination with balstilimab (AGEN2034) induced durable responses in patients with resistant/refractory ovarian cancer, according to findings from the phase 1 C-800 study (NCT03860272) presented at the 2023 SGO Annual Meeting on Women’s Cancer.1… Read more
by Hayley Virgil
Vadim Gushchin, MD, says that treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of negatively impacting health-related quality of life in ovarian cancer.
Combining hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery
by British Medical Journal
Regularly monitoring women with faulty BRCA genes that make them highly susceptible to ovarian cancer results in earlier stage diagnosis in those who want to defer preventive surgery, finds research published online in the Journal of … Read more
by Jordyn Sava
In the interview with Targeted Oncology, Anna Jo Bodurtha Smith, MD, discusses the effects various insurance types have on the quality of care of patients with gynecologic cancers.Whether a patient with gynecologic cancer has insurance or is … Read more
by Emily Henderson, B.Sc.
A global study into mucinous ovarian cancer could help oncologists recommend the best treatment for women who are diagnosed early with the condition.
By looking down a microscope for two different ‘patterns of invasion’ – the … Read more
A new type of technology can capture stray ovarian cancer cells from a simple blood test and successfully predict cancer in people who have a lesion or cyst in the pelvic region, according to a new study by a Wilmot … Read more
by Charles Bankhead
Women with cardiovascular conditions (CVCs) and ovarian cancer had better 2-year survival if they received a nonselective beta blocker (NSBB) at or around the time of cancer surgery, a review of medical records showed.
Two-year postoperative survival … Read more
Reviewed by Emily Henderson, B.Sc.
JMIR Publications recently published “Understanding the Information Needs of Patients With Ovarian Cancer Regarding Genetic Testing to Inform Intervention Design: Interview Study” in JMIR Cancer, which reported that experts in gynecological cancer care recommend that … Read more
Approach can help radiologists in a busy clinical practice assess lesions more quickly
The appearance of ovarian lesions on ultrasound is an effective predictor of cancer risk that can help women avoid unnecessary surgery, according to a new study published … Read more
by Gina Mauro
The iPocc trial indicated that patients with ovarian cancer experienced an improvement in progression-free survival when treated with intraperitoneal carboplatin plus paclitaxel compared with intravenous chemotherapy, but this benefit did not translate to overall survival.
The use
by Ariana Pelosci
Findings from a phase 3 study indicated that patients with uterine carcinosarcoma treated with paclitaxel and carboplatin experienced a better progression-free survival and non-inferior duration of overall survival vs paclitaxel plus ifosfamide.
A combination regimen of paclitaxel
… Read moreby Charles Bankhead
— More than 70% of patients reported one or more symptoms prior to diagnosis
More than 70% of women with high-risk early ovarian cancer had one or more symptoms of underlying disease, most often abdominal or pelvic … Read more
by Sophia George
Providing equal access to care will not by itself equalize outcomes between Black and white women.
Women from the African diaspora are disproportionately affected by high-grade and aggressive ovarian tumours. In the United States, mortality due to … Read more
by Steve Tally
Purdue-developed imaging drug allowed surgeons to find additional cancer lesions
Left image: A drug used for fluorescent imaging during ovarian cancer surgeries, which was just approved by the FDA, lights up cancer cells “like stars against a … Read more
— In vitro maturation can result in both embryos and oocyte vitrification, researcher says
by Amanda D’Ambrosio
In vitro maturation of immature eggs may be an effective method of fertility preservation for patients with gynecologic cancers, according to a prospective … Read more
